Connect Biopharma Holdings Ltd Dossier - Source-backed chat

Connect Biopharma Holdings Ltd

CNTBNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.00

Intrinsic Value $1.34median of 2 methodsbased on filings through 30 Jun 2026

Market Price $0.98Price as of 1 Oct 2026

UndervaluedIntrinsic value is 37% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $61.7M

Enterprise Value $34.7M

Shares Outstanding 60M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Connect Biopharma is a high-risk, high-reward clinical-stage biopharmaceutical company focused on transforming care for inflammatory respiratory diseases. The company's investment thesis centers entirely on its lead asset, rademikibart, a next-generation monoclonal antibody targeting IL-4Ȓ. Rademikibart has demonstrated a highly differentiated, potentially best-in-class clinical profile, including rapid bronchodilation effects that could disrupt the emergency and acute care settings for asthma and COPD—markets currently lacking approved biologics. With Phase 2 Seabreeze STAT Asthma enrollment completed in June 2026 and topline data expected in early September 2026, the company is approaching a binary valuation catalyst. A successful readout, followed by FDA alignment on a Phase 3 program and potential commercial milestones from its Greater China partnership with Simcere, provides substantial upside potential from current trading levels.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets8 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.00

Mean target$7.13

High · most bullish analyst$10.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The Phase 2 Seabreeze STAT trials fail to meet their primary efficacy endpoints or reveal unexpected safety concerns (such as severe adverse events), halting the development of rademikibart in acute settings. Because Connect Biopharma is a single-asset company with no clinical-stage backup candidates in its US pipeline, a clinical failure would severely impair the company's valuation. The company would be forced to rely solely on China royalties, and its cash runway into 2H 2027 would be insufficient to pivot, leading to severe capital preservation measures or restructuring.

Base CaseCentral scenario

The Phase 2 Seabreeze STAT Asthma and COPD trials deliver positive topline results in September 2026, demonstrating statistically significant improvements in FEV1 and a clean safety profile. The FDA aligns on a Phase 3 clinical program design by late 2026. Meanwhile, partner Simcere secures NMPA approval for rademikibart in atopic dermatitis in China, triggering milestone payments and establishing a low-double-digit royalty stream that extends Connect's cash runway beyond the second half of 2027 without immediate highly dilutive equity financing.

Bull CaseUpside scenario

Successful Phase 2 Seabreeze STAT readouts in September 2026 establish rademikibart as a best-in-class IL-4Rα antibody for acute asthma and COPD, paving the way for a lucrative global partnership and FDA Phase 3 alignment.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated Mechanism of Action: Rademikibart binds to IL-4Ȓ with a unique profile that promotes greater receptor internalization and rapid bronchodilation, unlike existing biologics like Dupixent.
Targeting Unmet Need in Acute Settings: By focusing on acute exacerbations of asthma and COPD in emergency settings, rademikibart targets a multi-billion dollar market with no currently approved biologic therapies.
Validated China Partnership: Partner Simcere has already submitted an NDA in China for atopic dermatitis based on positive Phase 3 data, positioning Connect to receive up to $110 million in remaining milestones plus tiered royalties.
Extended Cash Runway: Following a $20.2 million private placement in March 2026, the company's cash runway is extended into the second half of 2027, covering the critical Phase 2 readouts.

Key Investment Risks

Single-Asset Dependency: The company's US valuation is almost entirely dependent on the clinical success of rademikibart, with no backup clinical assets in development.
Binary Clinical Trial Risk: The upcoming Phase 2 Seabreeze STAT readouts in September 2026 represent a binary event; negative data would result in a catastrophic loss of shareholder value.
Funding and Dilution Risk: Advancing rademikibart into global Phase 3 trials will require substantial capital, necessitating future dilutive equity raises or strategic licensing deals if China milestones are delayed.

Thesis Invalidation Triggers

Failure of the Phase 2 Seabreeze STAT Asthma or COPD trials to meet primary efficacy endpoints.
Safety signals or serious adverse events in the Seabreeze STAT trials leading to clinical holds or trial discontinuations.
Rejection or significant delay of Simcere's New Drug Application (NDA) for rademikibart by the Chinese NMPA.
Inability to secure FDA alignment on a viable, cost-effective Phase 3 clinical trial design.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.